Cend Therapeutics Announces Acquisition of Impilo Therapeutics

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Cend Therapeutics, Inc., a clinical-stage biotech company, announced today that it has acquired Impilo Therapeutics, Inc. The combination expands Cend’s drug delivery capabilities to create a unique platform for targeted tissue penetrating delivery of nucleic acid-based medicines to solid tumor cancers.

Click to view original post

Advertise With Us